Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.38 |
| ▸ | DDX3X | O00571 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14644350 | 0.99 | BACE1 (0.46) | BACE1LMNAHPGDTSHRRAB9A | |
| SCHEMBL7600289 | 0.91 | BACE1 (0.46) | BACE1RAB9ANPC1EPHX1EPHX2 | |
| SCHEMBL7518098 | 0.89 | SMN1; SMN2 (0.52) | LMNARAB9ANPC1SMN1; SMN2NAMPT | |
| SCHEMBL7523778 | 0.89 | POLB (0.44) | BACE1HPGDRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7516029 | 0.89 | SMN1; SMN2 (0.51) | LMNARAB9ANPC1SMN1; SMN2NAMPT | |
| SCHEMBL7518919 | 0.89 | ROCK2 (0.47) | TSHRKMT2A | |
| SCHEMBL7519306 | 0.88 | POLB (0.44) | BACE1HPGDRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7518360 | 0.88 | ROCK2 (0.46) | TSHRKMT2A | |
| SCHEMBL8265116 | 0.85 | BACE1 (0.46) | BACE1LMNAHPGDTSHRRAB9A | |
| SCHEMBL7600611 | 0.85 | NAMPT (0.43) | LMNAHPGDTSHRRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018066-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | Schering Corporation & Pharmacopeia Drug Discovery Inc. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018066-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885LMNA 2420/4885HPGD 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.